Investor Presentaiton
SKAN
Aseptic Technologies is of strategic importance for SKAN
Five AT filled drugs on the market:
Customer
Janssen
Daiichi-Sankyo
Product area
Oncolytic virotherapy for brain cancer
Phase
Boehringer
Ingelheim
Cartilage repair for veterinary
applications
Oncology
*
Lentivirus used for the production of a
drug against multiple myeloma
PHARMACEUTICAL COMPANIES OF Johnson-Johnson
LEGEND
BIOTECH
ATARA BIO
Monotherapy for the treatment of
Epstein-Barr virus
Treatment of wounds in patients with
Krystal dystrophic epidermolysis bullosa in
collagen type VII alpha 1 chain gene
Aseptic Technologies (AT) provides automated, robot-
assisted process solutions for polymer closed vials (AT-
Closed VialⓇ Technology) for applications in cell and
gene therapy, a market segment that is growing +58%
p.a. (CAGR 2020-2024)(1).
Injection molded AT-Closed Vials® are suitable for
cryogenic storage at temperatures down to -196 c,
which is not possible with glass vials and is a unique
selling point
There are now five drugs on the market that are filled
using the closed vial solution of AT. The development
pipeline of drugs is in the range of approx. 400 active
ingredients.
SKAN increased its stake in AT to 85% and is
strengthening its Services & Consumables business,
fully in line with our long-term strategy.
November 2023
SKAN Group AG Investor Presentation
(1)
L.E.K. market study based on third-party data.
15View entire presentation